Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Okajima Masatsune
   2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [MNOV] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP and Head of Japanese Office
(Last)
(First)
(Middle)
C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300		 3. Date of Earliest Transaction (Month/Day/Year)
02/28/2019
(Street)

LA JOLLA, CA 92037		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/28/2019   M   35,700 A $ 7.34 189,280 D  
Common Stock 02/28/2019   M   85,000 A $ 2.54 274,280 D  
Common Stock 02/28/2019   M   63,750 A $ 2.46 338,030 D  
Common Stock 02/28/2019   M   80,000 A $ 4.1 418,030 D  
Common Stock 02/28/2019   M   42,500 A $ 4.1 460,530 D  
Common Stock 02/28/2019   M   105,000 A $ 2.64 565,530 D  
Common Stock 02/28/2019   M   15,000 A $ 3.24 580,530 D  
Common Stock 02/28/2019   M   105,000 A $ 3.09 685,530 D  
Common Stock 02/28/2019   M   30,000 A $ 3.91 715,530 D  
Common Stock 02/28/2019   M   120,000 A $ 3.91 835,530 D  
Common Stock 02/28/2019   M   100,000 A $ 6.1 935,530 D  
Common Stock 02/28/2019   M   105,000 A $ 7 1,040,530 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 7.34 02/28/2019   M     35,700   (1) 01/28/2020 Common Stock 37,500 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 2.54 02/28/2019   M     85,000   (2) 07/12/2021 Common Stock 85,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 2.46 02/28/2019   M     63,750   (3) 08/02/2021 Common Stock 63,750 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 4.1 02/28/2019   M     80,000   (4) 05/12/2023 Common Stock 80,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 4.1 02/28/2019   M     42,500   (5) 05/12/2023 Common Stock 42,500 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 2.64 02/28/2019   M     105,000   (6) 12/11/2023 Common Stock 105,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 3.24 02/28/2019   M     15,000   (7) 12/03/2024 Common Stock 15,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 3.09 02/28/2019   M     105,000   (8) 01/06/2025 Common Stock 105,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 3.91 02/28/2019   M     30,000   (9) 01/06/2026 Common Stock 30,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 3.91 02/28/2019   M     120,000   (10) 01/06/2026 Common Stock 120,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 6.1 02/28/2019   M     100,000   (11) 01/17/2027 Common Stock 100,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 7 02/28/2019   M     105,000   (12) 01/05/2028 Common Stock 105,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Okajima Masatsune
C/O MEDICINOVA, INC.
4275 EXECUTIVE SQUARE, SUITE 300
LA JOLLA, CA 92037		       VP and Head of Japanese Office  

Signatures

 /s/ Masatsune Okajima   03/04/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested.
(2) The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested.
(3) The option was granted on 8/3/2011, was subject to vesting based on achievement of performance criteria and vested in full on 6/14/2012.
(4) The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013.
(5) The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested.
(6) The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014.
(7) The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested.
(8) The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016.
(9) The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested.
(10) The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017.
(11) The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018.
(12) The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.